Genmab has appointed Matt Kiely as general manager for the United Kingdom, marking a key step in the company’s European commercial expansion. Kiely will lead Genmab’s UK operations as the biotech advances its antibody-based medicines into new markets and prepares for future product launches.

Founded in Copenhagen in 1999, Genmab has built a reputation as a leader in antibody science and is now strengthening its presence in Europe to bring its therapies to more patients. With operations already spanning multiple regions, the UK is set to become a cornerstone of Genmab’s broader growth strategy.

“Welcoming Matt to our team is a significant step in our mission to bring innovative medicines to more patients around the world,” said Brad Bailey, executive vice president and chief commercial officer at Genmab. “His outstanding track record in building high-performing organizations and launching successful cancer therapies makes him the ideal leader to drive our expansion in the UK, ensuring that we can deliver on our goal to bring treatments to patients in need.”

Kiely brings over 20 years of leadership experience in oncology, hematology, and market access, having held senior roles at GSK, Takeda, and Stemline Therapeutics. At Stemline, he played a pivotal role in establishing and expanding the company’s European commercial presence, building a strong organization from the ground up. Across his career, he has led multiple product launches and developed innovative market access strategies, with a focus on addressing patient needs across diverse healthcare systems.

“Throughout my career, I have been passionate about oncology innovation and am excited to join Genmab, a company at the forefront of antibody science and with a strong commitment to putting patients first,” Kiely said. “The UK healthcare environment holds potential for Genmab to make a difference for patients. I look forward to working with our teams to grow a strong organization and deliver on our shared vision.”

Genmab’s proprietary pipeline spans bispecific T-cell engagers, antibody-drug conjugates, immune checkpoint modulators, and effector function-enhanced antibodies.

The company has stated its vision to transform the lives of people with cancer and other serious diseases by 2030 through the development of what it calls “knock-your-socks-off” antibody medicines.

Kiely formally joined Genmab on September 1, and his appointment underscores the company’s ambition to cement a strong commercial footprint in the UK and wider European market as it advances its next wave of oncology therapies.